See how we are advocating for access to drugs and treatment for the brain tumour community.
Get Involved
There are so many ways you can help make a difference in the lives of patients and families today.
We are actively monitoring the COVID-19 situation. Learn More. Please enjoy our Virtual Programs.
Many voices, one goal - #EndBrainTumours
Many voices, one goal - #EndBrainTumours
See how we are advocating for access to drugs and treatment for the brain tumour community.
On May 1, 2020, the federal government’s Tier Assignment Committee added dexamethasone to the Tier 3 list. It is an important step, but there is far more action needed. Our position paper recognizes the vital importance of pharmaceutical drug products for persons with brain tumours, including dexamethasone.
Read our position paper hereEqual access to drugs that treat brain tumours and associated conditions, as well as the related financial burden, is an issue for families across Canada. Where a patient lives should never determine the treatment for a brain tumour.
Learn more about equal access across CanadaAs the leading organization in Canada focused on funding brain tumour research, we are the only group dedicated to overcoming this deadly disease.
Thanks to the support of donors, research funds are distributed every year to researchers across Canada who are examining the cause of and cure for brain tumours.
Read more about research funding hereBristol Myers Squibb (BMS) has announced their discontinuation of lomustine (CCNU), a chemotherapy drug that is often used to treat glioblastoma. Our advocacy letter to Bristol Myers Squibb outlines the potential impact that the discontinuation of lomustine may have on the brain tumour community.
The responsibility for health care falls to the thirteen (13) provinces and territories of Canada. Each provides basic hospital and physician services in exchange for federal funding support. The services they provide under this federal agreement do not include prescription or hospital drug coverage. Each province or territory makes independent decisions on WHAT pharmaceutical drugs they fund for the public, and HOW that drug funding is accessed.
Read Our Position Paper HereHealth Canada has approved Novocure’s Optune® for the treatment of newly diagnosed and recurrent glioblastoma (GBM). This milestone offers renewed hope and brings us one step closer to another treatment option for GBM patients in Canada. We will continue to keep our community informed on next steps and how we can work together to advocate for this treatment to be available to GBM patients in Canada.
Read Press ReleaseThis website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
This website uses the following additional cookies:
(List the cookies that you are using on the website here.)
Please enable Strictly Necessary Cookies first so that we can save your preferences!